MEETINGS - NASPE 2001, the North American Society of Pacing and Electrophysiology's 22nd annual scientific sessions (US) May 2001:
This article was originally published in Clinica
NASPE 2001, the North American Society of Pacing and Electrophysiology's 22nd annual scientific sessions, will be held at the Hynes Convention Center, in Boston, Massachusetts, on May 2-5. Topics to be addressed include: bradycardia, catheter ablation, clinical electrophysiology, clinical trials and epidemiology, health policy, pediatric, pharmacology, and tachycardia. For more information contact NASPE in the US. Tel: +1 847 940 2155. Fax: +1 847 940 2386. http://www.naspe.org
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.